The CB1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease

被引：64

作者：

Kelsey, J. E. ^{[1
,2
]}

Harris, O. ^{[2
]}

Cassin, J. ^{[2
]}

机构：

[1] Bates Coll, Dept Psychol, Lewiston, ME 04240 USA

[2] Bates Coll, Program Neurosci, Lewiston, ME 04240 USA

来源：

BEHAVIOURAL BRAIN RESEARCH | 2009年 / 203卷 / 02期

关键词：

Parkinson's; 6-OHDA; Rimonabant; CB1; receptors; L-DOPA; Forepaw stepping; RECEPTOR MESSENGER-RNA; MEDIAL FOREBRAIN-BUNDLE; DOPAMINERGIC-NEURONS; RAT MODEL; 6-HYDROXYDOPAMINE; LOCALIZATION; INJECTIONS; LESIONS;

D O I：

10.1016/j.bbr.2009.04.035

中图分类号：

B84 [心理学]; C [社会科学总论]; Q98 [人类学];

学科分类号：

03 ; 0303 ; 030303 ; 04 ; 0402 ;

摘要：

Acute injections of 8 mg/kg of 3,4-dihydroxy-L-phenylaianine (L-DOPA) or 0.05 mg/kg rimonabant equally improved contralateral forepaw stepping in rats with unilateral 6-hydroxydopamine (6-OHDA) lesions, and their combination improved stepping more than either drug alone. However, 0.05 mg/kg rimonabant did not alter the changes in stepping produced by acute injections of a dyskinesic dose of 35 mg/kg L-DOPA. Thus, not only is a cannabinoid antagonist monotherapeutic in this animal model of Parkinson's disease, but it also enhances the therapeutic effect of a moderate, but not a high, dose Of L-DOPA. (C) 2009 Elsevier B.V. All rights reserved.

引用

页码：304 / 307

页数：4

共 17 条

[1] Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: Studies on medial forebrain bundle and striatal lesions [J].

Chang, JW ;

Wachtel, SR ;

Young, D ;

Kang, UJ .

NEUROSCIENCE, 1999, 88 (02) :617-628

[2]

CHEN M, 2007, 2007 NEUR M PLANN SA

[3] Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism [J].

Fernandez-Espejo, E ;

Caraballo, I ;

de Fonseca, FR ;

El Banoua, F ;

Ferrer, B ;

Flores, JA ;

Galan-Rodriguez, B .

NEUROBIOLOGY OF DISEASE, 2005, 18 (03) :591-601

[4] Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease [J].

González, S ;

Scorticati, C ;

García-Arencibia, M ;

de Miguel, R ;

Ramos, JA ;

Fernández-Ruiz, J .

BRAIN RESEARCH, 2006, 1073 :209-219

[5]

Hohmann AG, 2000, SYNAPSE, V37, P71, DOI 10.1002/(SICI)1098-2396(200007)37:1<71::AID-SYN8>3.0.CO

[6]

2-K

[7] NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats [J].

Kelsey, JE ;

Mague, SD ;

Pijanowski, RS ;

Harris, RC ;

Kleckner, NW ;

Matthews, RT .

PSYCHOPHARMACOLOGY, 2004, 175 (02) :179-188

[8] The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat [J].

Kelsey, John E. ;

Langelier, Nicole A. ;

Oriel, Brad S. ;

Reedy, Catherine .

PSYCHOPHARMACOLOGY, 2009, 201 (04) :529-539

[9] Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat [J].

Kirik, D ;

Rosenblad, C ;

Björklund, A .

EXPERIMENTAL NEUROLOGY, 1998, 152 (02) :259-277

[10] Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets [J].

Lastres-Becker, I ;

Cebeira, M ;

de Ceballos, ML ;

Zeng, BY ;

Jenner, P ;

Ramos, JA ;

Fernández-Ruiz, JJ .

EUROPEAN JOURNAL OF NEUROSCIENCE, 2001, 14 (11) :1827-1832

← 1 2 →